PHARMACYTE BIOTECH, INC. Acquired Finite-lived Intangible Asset, Residual Value
PHARMACYTE BIOTECH, INC. (PMCB) had Acquired Finite-lived Intangible Asset, Residual Value of $2.00 million as of 2016-01-31, per its 10-Q filed 2016-03-08.
Discontinued › Notes
us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue · last filed 2016-03-08
- 2016-01-31: Acquired Finite-lived Intangible Asset, Residual Value $2.00M.
- 2015-10-31: Acquired Finite-lived Intangible Asset, Residual Value $2.00M.
- 2015-07-31: Acquired Finite-lived Intangible Asset, Residual Value $2.00M.
| Period end | Acquired Finite-lived Intangible Asset, Residual Value |
|---|---|
| 2016-01-31 | $2.00M 10-Q · filed 2016-03-08 |
| 2015-10-31 | $2.00M 10-Q/A · filed 2016-01-19 |
| 2015-07-31 | $2.00M 10-Q/A · filed 2016-01-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |